Posts Tagged ‘Emory’
Monday, November 8th, 2010
 Space Shuttle
ATLANTA – Manned space exploration may be on a back burner right now, but NASA is obviously still looking at how to protect astronauts from exposure to space radiation and other hazards of space travel. Researchers from Emory University’s Winship Cancer Institute and the Medical College of Georgia are launching a new cancer research initiative – literally.
The National Aeronautics and Space Administration (NASA) has awarded a team of investigators from both institutions $7.6 million over five years to study how a component of space radiation may induce lung cancer.
The award establishes a NASA Specialized Center of Research (NSCOR), consisting of a team of scientists with complementary skills who work closely together to solve a set of research questions. Ya Wang, PhD, professor of radiation oncology at Emory University School of Medicine and Winship Cancer Institute, is director of the NSCOR at Emory.
Interplanetary space travel could expose astronauts to conditions where they are chronically exposed to types of radiation not normally encountered on earth. One of these is high energy charged particles (HZE), which results in complex damage to DNA and a broader stress response by the affected cells and tissues.
There is no epidemiological data for human exposure to HZE particles, although some estimates have been made studying uranium miners and Japanese atomic bomb survivors, says Wang.
Animal experiments show that HZE particle exposure induces more tumors than other forms of radiation such as X-rays or gamma rays. Because it is a leading form of cancer, lung cancer can be expected to be prominent among increased risks from radiation even though astronauts do not smoke. However, the risk for astronauts remains unclear because the dose of HZE astronauts are expected to receive is very low, Wang says.
The Emory-MCG researchers will probe whether the broader stress response induced by HZE particles amplifies cancer risk. Investigators will collaborate with physicists at Brookhaven National Laboratory to gather information on HZE’s effects. Individual projects include the study of how cells repair DNA damage induced by HZE particles, how HZE particles generate oxidative stress, and how they trigger regulatory changes in DNA known as methylation.
Tags: Emory, Georgia, grant, Medical College of Georgia, NASA, space raditiation Posted in Biotech, Georgia | Comments Off
Tuesday, October 26th, 2010
ATLANTA—Researchers at Emory University and the Georgia Institute of Technology will join forces against head and neck cancers and pancreatic cancer using two grants from the National Cancer Institute’s Cancer Nanotechnology Platform Partnerships (CNPP) program. The cooperative five-year grants totaling $4.7 million will be used to develop nanoparticles as diagnostic and therapeutic tools against cancers.
The first grant totals more than $2.3 million over five years and is awarded to Dong Moon Shin, MD, professor of hematology, medical oncology and otolaryngology and director of the Winship Cancer Chemoprevention program, and Mostafa El-Sayed, PhD, Regents professor of chemistry and biochemistry and director of the Laser Dynamics Laboratory at Georgia Institute of Technology.
Their project, titled “Toxicity and efficacy of gold nanoparticle photothermal therapy in cancer,” is aimed at head and neck cancer, which develops in the soft tissues of the mouth and throat.
“We are excited and grateful for the opportunity to combine our laboratories’ biological and chemical expertise and to develop gold nanoparticle phototherapy into an effective tool against head and neck cancer,” says Shin.
When a laser is tuned to certain wavelengths, gold nanoparticles will absorb the energy and convert it to heat, thanks to a phenomenon known as “surface plasmon resonance.” Directing the nanoparticles to “home in” on cancer cells enables the laser to selectively kill them.
Researchers plan to target the molecule EGFR (epidermal growth factor receptor), which is found on almost all head and neck cancers, by binding the gold nanoparticles to antibodies against EGFR. Studies in animals on the toxicity of gold nanoparticles and how fast they move within the body are necessary before application in humans.
The second NCI grant for nearly $2.4 million over five years will be used to develop magnetic iron oxide nanoparticles as tools against pancreatic cancer, one of the most deadly of all cancer types. The principle investigators are Lily Yang, MD, PhD, associate professor of surgery and Hui Mao, PhD, associate professor of radiology and Center for Systems Imaging, both at Emory University School of Medicine.
The project, titled “Theranostic nanoparticles for targeted treatment of pancreatic cancer,” aims to combine the function of MRI visualization with drug delivery capabilities for pancreatic cancer therapy and diagnosis (thera – nostics).
Using magnetic iron oxide nanoparticles developed by Yang and Mao and their teams, researchers plan to improve the delivery of chemotherapeutic agents by directing drug-carrying nanoparticles to the molecule uPAR (urokinase plasminogen activator receptor), which is prevalent in pancreatic cancer cells.
Magnetic iron oxide nanoparticles will be loaded with different types of drug molecules that can be released at the site of the tumor or even inside of the tumor cells. “These nanoparticles can be tracked by magnetic resonance imaging (MRI),” says Yang, “so we will test our ability to monitor drug delivery and treatment responses with imaging technology.”
Other institutions receiving CNPP grants are Cedars-Sinai Medical Center; Children’s Hospital of Los Angeles; University of North Carolina; Northeastern University; Northwestern University; Rice University; University of Cincinnati; University of Nebraska Medical Center; University of New Mexico Health Sciences Center; and the University of Utah.
Tags: cancer treatment, Emory, GA Tech, Nanotech, Pharma, University research Posted in Biotech, Georgia, Money, Nanotech, University Tech | 1 Comment »
Wednesday, October 20th, 2010
ATLANTA – Southeast BIO (SEBIO), a regional nonprofit organization dedicated to fostering the growth of the Southeast’s life sciences industry, has named the best life sciences deals in the Southeast, as determined by a Selection Committee comprised of regional and national venture capitalists. These companies, both early- and later-stage, will participate in the upcoming SEBIO Investor Forum being held on November 3-4, 2010 at the Ritz-Carlton, Buckhead in Atlanta, Georgia.
Those companies chosen for the EARLY/Stage event are seeking their first rounds of venture capital and/or angel investment. During the Investor Forum, the companies will participate in an advisory session led by active early-stage investors. The MAIN/Stage presenting companies have generally completed at least one round of institutional financing and will each have the opportunity to make a ten minute pitch to the full conference audience.
Since 1999, companies that have participated in the SEBIO Investor Forum have raised over $2.5 billion in public and private offerings.
SEBIO has also selected four finalists for its Fourth Annual BIO/Plan Competition, a program developed to promote the creation of new, fundable life science companies based in the Southeast. Working closely with technology transfer offices and entrepreneurs throughout the region, the competition brings forward opportunities from leading Southeastern research universities and research centers. The BIO/Plan Competition received forty applications earlier this year from all across the Southeast.
SEBIO 2010 MAIN/Stage Companies
Avancen MOD Corporation (Mt. Pleasant, SC)
EGEN, Inc. (Huntsville, AL)
Intelliject, Inc. (Richmond, VA)
InVasc Therapeutics, Inc. (Tucker, GA)
RFS Pharma, LLC (Tucker, GA)
Visioneering Technologies, Inc. (Alpharetta, GA)
SEBIO 2010 EARLY/Stage Companies
Ariste Medical, LLC (Memphis, TN)
Atlanta Catheter Therapies, Inc. (Atlanta, GA)
AXOXY Laboratories, LLC (Gainesville, FL)
Bioshape Solutions, Inc. (Research Triangle Park, NC)
CvergenX, Inc. (Tampa, FL)
Endomimetics, LLC (Birmingham, AL)
GeneCapture, Inc. (Huntsville, AL)
Grace Innovative Technologies, Inc. (Mobile, AL)
HemoSonics, LLC (Charlottesville, VA)
NeurOp, Inc. (Atlanta, GA)
Physcient, Inc. (Durham, NC)
Restorative Physiology Group, LLC (North Charleston, SC)
Scytel Research (Chapel Hill, NC)
Vascular Pharmaceuticals, Inc. (Cary, NC)
Vivo Biosciences, Inc. (Birmingham, AL)
SEBIO 2010 BIO/Plan Finalists:
FibroTherapeutics, Inc. (Medical University of South Carolina)
NRG Biotechnology (Morehouse School of Medicine)
Reactive Diagnostics, Inc. (Georgia Institute of Technology)
SPECTROPATH Medical (Emory University)
Tags: Atlanta, Emory, GA, GA Tech, Investor Forum, life sciences, Medical University of SC, Morehouse School of Medicine, NC, Pharma, presenting companies, SC, SEBIO, VA Posted in Alabama, Biotech, Carolinas, Events, Georgia, North Carolina, Other SE, Pharma, Potomac, South Carolina, Virginia | Comments Off
Monday, October 4th, 2010
ATLANTA—Results of a study reported today show promise for changing the way U.S. health care may one day be delivered. This new way of delivering health care would focus on predicting health as opposed to waiting for disease to begin.
The researchers say that by assessing fundamental physiological and psychological processes to predict potential health risks–and by providing a health partner to help people develop and implement their own health goals—there is a greater chance of staying healthy throughout life.
An article describing the study, conducted by researchers at the Emory/Georgia Tech Predictive Health Institute, appears online a www.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2010.03107.x/full and in the October 2010 issue of the Journal of the American Geriatrics Society.
Predictive health should be less expensive
Study researchers are also aiming to define health as effectively as modern science permits, and to learn what physical, psychological and emotional factors describe and predict health. With this knowledge, interventions could be designed that are affordable and effective instead of waiting for disease and illness to set in.
“One premise of predictive health is that it should be less expensive, more efficient and thus yield a greater return on the investment of keeping people healthy as opposed to waiting for illness and disease,” says Kenneth Brigham, MD, associate vice president and director of Emory University’s Predictive Health Initiative.
For just that reason, the term ‘predictive health,’ has been chosen to emphasize prediction instead of diagnosis, and health instead of disease, says Brigham, author of the paper. Thus, the aim of predictive health is to define, predict and maintain health–throughout the entire lifespan.
Researchers are finding one way to accomplish this goal is through health assessments and matching participants with health partners.
The current study collected detailed data from participants on their family situation, anxiety level, depression, diet and exercise habits as well as physical measurements such as blood pressure, heart rate, body fat, bone density and various biomarkers. The data were then assembled into a health assessment report, a summary and interpretation of the information.
Results show significant effects
At this point, health partners provided more information and support for each participant to develop a health action plan aimed at meeting specific goals to help participants develop and maintain their optimum health.
Study results show statistically significant reductions in cholesterol levels, blood pressure, blood glucose, body fat, depression, anxiety and stress.
“We have found that in just six months time, many of our participants have experienced significant improvements in metabolic, cardiovascular, immune and emotional health,” says Brigham. Longer-term follow-up studies are planned.
Reported in a special issue called State-of-the-Art in Longitudinal Studies on Aging, “Predictive Health: The Imminent Revolution in Health Care” is available in PDF at www.onlinelibrary.wiley.com/doi/10.1111/j.1532-5415.2010.03107.x/pdf.
The upcoming Sixth Annual Emory/Georgia Tech Predictive Health Symposium will continue to explore this new paradigm of health care with national and international experts in the field. It is scheduled for Dec. 13-14, 2010 at the Emory Conference Center, Atlanta. To register, visit www.acteva.com/go/predictivehealth
Tags: Atlanta, cutting healthcare costs, Emory, healthcare study, predictive health Posted in Georgia, Healthcare, Studies, surveys, reports | 2 Comments »
Friday, September 24th, 2010
ATLANTA – Nearly a decade of war in the Middle East has led to Posttraumatic Stress Disorder problems for between 20 and 30 percent of U.S. veterans who served in Iraq and Afghanistan. Now, researchers at Emory in Atlanta are using a combination drug and virtual reality therapy to help them.
The study led by PTSD researchers Barbara Rothbaum, PhD, ABPP, and Kerry Ressler, MD, PhD, and funded by the National Institute of Mental Health (NIMH) is currently under way at Emory, testing the combination of the drug d-cycloserine (DCS) with virtual reality therapy.
A large part of the problem PTSD patients have is fear of the memory itself, she says. “Although the memories will never really go away, we believe that the combination of the virtual reality exposure therapy and DCS will make it easier for patients to learn that they can handle their memories.”
Previous studies by Emory and Yerkes neuroscientist, Michael Davis, PhD, have shown that DCS enhances the extinction of fear.
Ressler, Rothbaum, and Davis completed the first human trial using DCS with Virtual Reality Exposure Therapy for acrophobia, or fear of heights, in 2004.
The encouraging outcome of that study and subsequent studies on social phobia and obsessive compulsive disorder inspired the researchers to reach out to victims of trauma with the same combination of DCS and virtual reality therapy.
“This particular combination of treatment techniques and medication arises from years of studying fear and, most importantly, what decreases fear,” says Rothbaum. “We are very excited about the prospects of this combined therapy.”
The first participant treated with the virtual Iraq exposure therapy showed a 56 percent decrease in PTSD scores following four therapy sessions.
“Persons with PTSD experience both psychological and physical effects that can worsen with time,” Ressler explains. “We believe this study is opening up some new doors that will help us get people back to their normal lives quickly, and with more robust and long-lasting results.”
For information about study participation, call (404) 712-8300 or email at tarp@emory.edu
Tags: Afghanistan, Atlanta, D-cycloserine, Emory, Irag, Posttraumatic Stress Disorder, PTSD, PTSD therapy, veterans, virtual reality Posted in Georgia, Healthcare, University Tech | Comments Off
Thursday, August 12th, 2010
ATLANTA – Emory Vaccine Center at Yerkes National Primate Research Center, Emory University has won a five-year, $15 million National Institutes of Health grant to to study human immune responses to vaccination.
Scientists in a new Center for Systems Vaccinology will employ the modern analytic tools of systems biology to understand the immune responses vaccines stimulate in humans and will use this knowledge to guide design of vaccines against HIV, malaria and other global pandemics.
Researchers at the center will address a major challenge thus far in the development of vaccines – that the effectiveness of vaccination can only be ascertained after vaccinated individuals have been exposed to infection.
Bali Pulendran, PhD, Charles Howard Candler Professor in the Department of Pathology and Laboratory Medicine at Emory University, the Emory Vaccine Center and Yerkes Research Center, is principal investigator of the center. Rafi Ahmed, PhD, director of the Emory Vaccine Center and a Georgia Research Alliance Eminent Scholar, will serve as co-PI. To study vaccine-induced immunity in humans, they will use a multidisciplinary approach Pulendran developed.
Pulendran’s approach, which he published in Nature Immunology in November 2008, involves immunology, genomics and bioinformatics to predict the immunity of a vaccine without exposing individuals to infection.
This systems biological approach permits researchers to observe a global picture of all the nearly 30,000 genes, proteins and cells participating in immune responses to vaccination. Using this approach, the investigators were able to identify signatures of gene expression in the blood a few days after vaccination that could predict with up to 90 percent accuracy the strength of the immune response to the yellow fever vaccine, one of the most successful vaccines ever developed.
Researchers working in the new Center for Systems Vaccinology will determine whether Pulendran’s approach can be used to predict the effectiveness of other vaccines, including common vaccines against influenza, pneumococcal disease and shingles. With each of these vaccines, a substantial proportion of elderly individuals do not launch protective immunity. Researchers will work to identify gene signatures that would identify such individuals. The ability to successfully predict the immunity and efficacy of vaccines would facilitate the rapid evaluation of new and emerging vaccines, and the identification of individuals who are unlikely to be protected by a vaccine.
This effort will rely on the analysis of well-characterized young and elderly human cohorts, and use cutting-edge technologies such as genomics and proteomics to study the molecular and cellular dynamics of vaccine-induced immunity in humans with great precision. The center will comprise a highly integrated and interdisciplinary team of researchers and clinicians in areas as diverse as immunology, vaccinology, clinical medicine, computational modeling and mathematics.
Tags: Atlanta, Emory, NIH grant, vaccination response study Posted in Biotech, Healthcare, Money, University Tech | Comments Off
Monday, July 12th, 2010
ATLANTA—A new sequencing enrichment platform called the Fluidigm Access Array will allow Emory Genetics Laboratory to rapidly amplify and enrich regions of DNA for its “next-generation” sequencing ability and genetic testing.
The new system will be used to enhance three next-generation sequencing tests recently developed and launched at Emory for X-linked intellectual disability, congenital muscular dystrophy and congenital disorders of glycosylation (CDG)—three groups of rare but extremely serious developmental disabilities and degenerative neurological disorders present in newborns, children and adults.
The Fluidigm Access Array system can concurrently enrich up to 480 target regions or 480kb of DNA sequence, and can facilitate amplification of 48 unique samples at a time using an “integrated fluidic circuit chip.”
It also uses a unique method of tagging and identifying amplified sequences, which simplifies sample preparation and maximizes output in genetic testing.
The Access Array system will complement new equipment recently acquired by Emory Genetics Laboratory: the Applied Biosystem SOLiD system and Raindance Technologies’ RDT 1000 instrument, which are used for the three new sequencing panels.
In addition to expanding its next generation testing menu, Emory Genetics Laboratory will use the Fluidigm Access Array system to assist in the development of its new genotyping chip.
The Recessive Disorders Screening Panel, scheduled for launch later this summer, will target 90 diseases with more than 473 mutations for use in carrier screening and prenatal diagnosis.
“This new combination of next-generation sequencing equipment and targeted enrichment technology will allow our laboratory to deliver the most cutting-edge, efficient and accurate genetics diagnosis possible for a variety of rare genetic diseases,” says Madhuri Hegde, PhD, FACMG, senior director of Emory Genetics Laboratory and associate professor in the Department of Human Genetics.
Emory Genetics Laboratory, within the Department of Human Genetics at Emory University School of Medicine, is a comprehensive clinical genetics testing laboratory (cytogenetics, molecular and biochemical services) specializing in molecular cytogenetics, rare disease testing and newborn screen confirmatory testing. For more information, visit geneticslab.emory.edu.
Tags: Atlanta, DNA sequencing platform, Emory, Georgia Posted in Biotech, Georgia, Pharma, University Tech | Comments Off
Wednesday, June 23rd, 2010
ATLANTA–A new animal model of atherosclerosis has allowed researchers to identify a host of genes turned on or off during the initial stages of the process, before a plaque appears in the affected blood vessel.
The model is the first to definitively show that disturbances in the patterns of blood flow in an artery determine where atherosclerosis will later appear, says senior author Hanjoong Jo, PhD, Ada Lee and Pete Correll professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
The first author of the paper is Chih-Wen Ni, a graduate student in biomedical engineering.
Atherosclerosis describes a process where the arterial walls thicken and harden, because of a gradual build-up of white blood cells, lipids and cholesterol. This process can lead to plaque formation, and eventually to heart attacks and strokes.
Jo says his team’s results could provide insight into how aerobic exercise, known to provide protection against atherosclerosis, improves the patterns of blood flow and encourages protective genes to turn on in blood vessels.
Scientists have previously observed that atherosclerosis occurs preferentially in branched or curved regions of arteries, because of the “disturbed flow” branches and curves create. Constant, regular flow of blood appears to promote healthy blood vessels, while low or erratic flow can lead to disease.
The standard laboratory model of atherosclerosis has scientists feeding a high-fat diet to mice with mutations in a gene (ApoE) involved in removing fat and cholesterol from the blood. Even then, atherosclerosis usually takes a few months to develop. In these models, clogs in a mouse’s arteries tend to appear in certain places, such as the aortic arch, but flow patterns are set up at birth and thus are poor gauges of cause and effect, Jo says.
“We have developed a model where we disturb blood flow in the carotid artery by partial ligation, and atherosclerosis appears within two weeks,” he says. “This rapid progression allows us to demonstrate cause and effect, and to examine the landmark events at the beginning of the process.”
Jo says that endothelial cells, which form the inner lining of blood vessels, are equipped with sensors that detect changes in fluid flow.
“Disturbed flow is what causes the endothelial cells to become inflamed,” he says.
The inflammation resulting from “bad flow” conditions in a stretch of artery causes white blood cells to accumulate there, followed by buildup of cholesterol and lipids and plaque formation.
Just 48 hours after blood flow in the carotid arteries was disturbed, Ni and colleagues dissected the carotid arteries from the mice and used genome-wide microarray technology to identify hundreds of genes that were turned on or off in the endothelial cells.
In past experiments, scientists grew endothelial cells in dishes to probe how different patterns of fluid flow affected their patterns of genes. However, growing cells in dishes alters them enough that many of the genes Jo’s team found have not been identified before in this context.
For example, the team showed that the gene LMO4 – not previously known to be involved in atherosclerosis — is turned on in their mouse model and also in human coronary arteries. Scientists studying breast cancer think LMO4 is involved in tumor migration and invasion, making an interesting parallel between atherosclerosis and cancer, Jo says.
He says his laboratory is now probing which of the newly identified genes are most important in atherosclerosis and searching for ways to manipulate them with drugs or genetic techniques, with an eye towards possible diagnostic and pharmaceutical applications.
The research was supported by the National Heart, Lung and Blood Institute, the Ada Lee and Pete Correll Professorship at Emory and Georgia Tech, and the World Class University project at Ewha Womans University in South Korea.
The results were published June 15 in Blood, the journal of the American Society of Hematology.
Tags: Ada Lee, atherosclerosis, Atlanta, Emory, Georgia Tech, Healthcare, Pete Correll, University research Posted in Biotech, Georgia, Healthcare, University Tech | Comments Off
Tuesday, March 30th, 2010
ATLANTA – NeurOP Corp. has inked a collaboration deal with Bristol-Myers Squibb (NYSE:BMY) focused on developing new treatments for people with major depression who fail to get relief from current treatments.
The deal includes a $1.5 million upfront payment and funds a two-year research collaboration. It also includes the potential for NeurOP to nab up to $75 million in potential milestone payments for for the successful development of a compound in major depression and royalties on worldwide sales of commercialized compounds.
It is developing a compound class comprised of NR2B subunit-specific N-methyl-D-aspartate (NMDA) receptor antagonists.
We think NeurOP has a shot a making considerable chunks of cash. A large number of people who suffer from depression find only temporary or insufficient relief from current medications. The famous writer David Foster Wallace recently hanged himself when he could not find a suitable anti-depressant medicine and he is only one of many people who suffer from what Winston Churchill called “The Black Dog.”
The company also has technology aimed at pain relief, another sure-fire money-maker if it works better than products already available.
“NeurOp’s collaboration with Bristol-Myers Squibb will explore new treatment options for the millions of patients suffering from major depression who are unable to get relief from available treatments,” added Vincent La Terza, head of corporate development, NeurOp.
NeurOp has offices and laboratory facilities in EmTech Bio, a life sciences incubator located on the campus of Emory University in Atlanta, Georgia.
The company has raised $2.2MM to date through grants and convertible debt instruments with angel investors led by The Blue Grass Angels.
In 2000, the NeurOp founders initiated a collaboration with Dr. Dennis Liotta, a professor in the Emory Department of Chemistry to translate these promising concepts into medicines.
Dr. Liotta is a renowned medicinal chemist and has helped discover and develop several pharmaceuticals currently in use or undergoing clinical evaluation. About 75 percednt of all HIV patients worldwide are treated with antiviral compounds discovered or developed in Dr. Liotta’s lab.
Tags: Atlanta, Biotech, depression treatment, Emory, NeurOP, Pharma Posted in Biotech, Georgia, Money, Pharma | Comments Off
Tuesday, March 30th, 2010
 A macrophage capturing a virus coated in antibodies.
ATLANTA – The Emory Institute of Drug Discovery and Zirus Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. In the lab, the underlying Zirus technology has already stopped viruses that cause flu, AIDS,herpes, measles, Ebola, and dengue fever, among others, from replicating.
Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.
Zirus has also identified a number of drugs already approved for indications other than infectious disease that appear to block Zirus targets. These drugs have the potential to reach the market quickly to address significant unmet medical needs for infectious diseases.
William O’Brien, M.D., CMO of Zirus stated, “Over the years viruses have shown that they can outsmart vaccines and anti-viral drugs such as protease inhibitors by mutating and developing resistance.
“As a result, there is no effective vaccine for HIV, each year we need a new vaccine for the seasonal flu, the effectiveness of vaccines for variations of swine flu and avian flu remain questionable, and the cocktail of drugs taken by AIDS patients is constantly changing.
“Each of these viruses, however, share a common element; they must invade our cells (human host cells) and hijack our genetic machinery in order to reproduce (Video of how flu viruses replicate) The Zirus technology allows us to identify which genes and pathways are employed by the viruses inside our cells, and by blocking them we can stop the virus from replicating.
David Perryman, CEO of Zirus, added, “The collaboration with Emory is designed as a true partnership between Zirus and a world class group of chemists with a track record of designing successful drugs.”
The Emory team is being led by Dennis Liotta, the Samuel Candler Dobbs Professor of Chemistry and head of the Emory Institute of Drug Discovery.
Liotta said, “While I have successfully worked for many years developing anti-viral drugs, the Zirus approach to blocking host cell genes and gene products represents a new paradigm in dealing with infectious disease that may address some of the shortcomings of conventional programs. Infectious disease needs a multi-prong attack, and the Zirus host targets appear to represent the ‘third leg of the stool’ along with vaccines and traditional anti-virals that attack the virus.
The Emory Institute for Drug Discovery was established in August 2009, with the dual mission of carrying out early-stage discovery and preclinical drug research aimed at developing small-molecule therapeutics and training new generations of researchers in a multidisciplinary drug discovery environment.
Tags: anti-viral drugs, Atlanta, Biotech, Emory, Pharma, University research, Zirus Posted in Biotech, Georgia, Pharma, University Tech | Comments Off
|
|
|